Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV

European journal of cancer (Oxford, England : 1990)1 Jun 1997Cited by 71 (Europe PMC)

PMID9376196DOI10.1016/s0959-8049(97)00072-5PepBankPUB-09376196

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In nude mice with DU-145 prostate cancer xenografts, triptorelin did not significantly inhibit tumour growth versus saline.
In plain wordsIn mice with prostate cancer xenografts, triptorelin did not significantly inhibit tumour growth compared with saline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeTumour growth
Study
mousen: not reported in source
DU-145 prostate cancer xenografts in male nude mice
Comparator
Saline
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Agonist [D-Trp6]LH-RH did not significantly inhibit tumour growth.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp6]LH-RH (triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on the growth of an androgen-independent prostate cancer cell line, DU-145, xenografted into nude mice.
Summary · context
Xenografts were grown in male nude mice, and after 4 weeks, the animals were treated either with saline (control) or with one of the analogues.
Summary · context
Treatment was given for 4 weeks.
Report a problemFND-0937619601
02AnimalAnimal study (in vivo)Efficacy outcome
In nude mice with DU-145 xenografts, cetrorelix reduced final tumour volume to 121.4 +/- 45 mm3 versus 577 +/- 155 mm3 with saline (P < 0.01).
In plain wordsIn mice with prostate cancer xenografts, cetrorelix reduced final tumour volume compared with saline.
Peptide
Cetrorelix
Outcome
DecreaseFinal tumour volume
Study
mousen: not reported in source
DU-145 prostate cancer xenografts in male nude mice
Comparator
Saline control
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Measurements
Final tumour volume
121.4 mm3
Cetrorelix
Final tumour volume
577 mm3
Saline control
Source sentences
Summary
The final tumour volume in control animals injected with saline was 577 +/- 155 mm3 and that of animals treated with Cetrorelix only 121.4 +/- 45 mm3 (P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp6]LH-RH (triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on the growth of an androgen-independent prostate cancer cell line, DU-145, xenografted into nude mice.
Summary · context
Xenografts were grown in male nude mice, and after 4 weeks, the animals were treated either with saline (control) or with one of the analogues.
Summary · context
Treatment was given for 4 weeks.
Report a problemFND-0937619602
03AnimalAnimal study (in vivo)Efficacy outcome
In nude mice with DU-145 xenografts, cetrorelix reduced serum LH to 0.08 +/- 0.02 ng/ml versus 1.02 +/- 0.1 ng/ml in controls (P < 0.05).
In plain wordsIn mice with prostate cancer xenografts, cetrorelix reduced serum LH compared with saline controls.
Peptide
Cetrorelix
Outcome
DecreaseSerum LH concentration
Study
mousen: not reported in source
DU-145 prostate cancer xenografts in male nude mice
Comparator
Saline control
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Measurements
Serum LH
0.08 ng/ml
Cetrorelix
Serum LH
1.02 ng/ml
Controls
Source sentences
Summary
Serum levels of LH were decreased to 0.08 +/- 0.02 ng/ml (P < 0.05) in the Cetrorelix treated group as compared to 1.02 +/- 0.1 ng/ml for the controls, and testosterone levels were reduced to castration levels (0.01 +/- 0.01 ng/ml).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp6]LH-RH (triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on the growth of an androgen-independent prostate cancer cell line, DU-145, xenografted into nude mice.
Summary · context
Xenografts were grown in male nude mice, and after 4 weeks, the animals were treated either with saline (control) or with one of the analogues.
Summary · context
Treatment was given for 4 weeks.
Report a problemFND-0937619603
04AnimalAnimal study (in vivo)Efficacy outcome
In nude mice with DU-145 xenografts, cetrorelix reduced serum testosterone to castration levels of 0.01 +/- 0.01 ng/ml.
In plain wordsIn mice with prostate cancer xenografts, cetrorelix reduced testosterone to castration levels.
Peptide
Cetrorelix
Outcome
DecreaseSerum testosterone concentration
Study
mousen: not reported in source
DU-145 prostate cancer xenografts in male nude mice
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Measurements
Serum testosterone
0.01 ng/ml
Cetrorelix
Source sentences
Summary
Serum levels of LH were decreased to 0.08 +/- 0.02 ng/ml (P < 0.05) in the Cetrorelix treated group as compared to 1.02 +/- 0.1 ng/ml for the controls, and testosterone levels were reduced to castration levels (0.01 +/- 0.01 ng/ml).
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp6]LH-RH (triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on the growth of an androgen-independent prostate cancer cell line, DU-145, xenografted into nude mice.
Summary · context
Xenografts were grown in male nude mice, and after 4 weeks, the animals were treated either with saline (control) or with one of the analogues.
Summary · context
Treatment was given for 4 weeks.
Report a problemFND-0937619604
05AnimalAnimal study (in vivo)Mechanism
In nude mice with DU-145 xenografts, tumour EGF receptors were significantly downregulated after cetrorelix treatment.
In plain wordsIn mice with prostate cancer xenografts, tumour EGF receptors decreased significantly after cetrorelix treatment.
Peptide
Cetrorelix
Outcome
DecreaseTumour EGF receptors
Study
mousen: not reported in source
DU-145 prostate cancer xenografts in male nude mice
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Specific receptors for EGF and LH-RH in DU-145 tumours were significantly downregulated after treatment with Cetrorelix, RC-3940-II and RC-3950-II.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp6]LH-RH (triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on the growth of an androgen-independent prostate cancer cell line, DU-145, xenografted into nude mice.
Summary · context
Xenografts were grown in male nude mice, and after 4 weeks, the animals were treated either with saline (control) or with one of the analogues.
Summary · context
Treatment was given for 4 weeks.
Report a problemFND-0937619605
06AnimalAnimal study (in vivo)Mechanism
In nude mice with DU-145 xenografts, tumour LH-RH receptors were significantly downregulated after cetrorelix treatment.
In plain wordsIn mice with prostate cancer xenografts, tumour LH-RH receptors decreased significantly after cetrorelix treatment.
Peptide
Cetrorelix
Outcome
DecreaseTumour LH-RH receptors
Study
mousen: not reported in source
DU-145 prostate cancer xenografts in male nude mice
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated · 4 weeksAs given in this study (mouse).
Source sentences
Summary
Specific receptors for EGF and LH-RH in DU-145 tumours were significantly downregulated after treatment with Cetrorelix, RC-3940-II and RC-3950-II.
3 context sentences(design, population, supporting numbers)
Summary · context
The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp6]LH-RH (triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on the growth of an androgen-independent prostate cancer cell line, DU-145, xenografted into nude mice.
Summary · context
Xenografts were grown in male nude mice, and after 4 weeks, the animals were treated either with saline (control) or with one of the analogues.
Summary · context
Treatment was given for 4 weeks.
Report a problemFND-0937619606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.